SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study.

Fahimeh Safarnezhad Tameshkel,Shabnam Abedin Dargoush,Bahareh Amirkalali,Saeedeh Javadi,Ali Ghiaseddin,Yousef Alimohamadi,Ali Basi,Mahin Jamshidi Makiani,Farhad Zamani,Mohammad Hadi Karbalaie Niya

Frontiers in medicine（2022）

引用 0|浏览7

暂无评分

摘要

Full vaccination of COVID-19 by BBIBP-CorV in immunocompromised patients such as cancer patients is safe and effective and could induce antibody response but in lower levels compared to healthy people. Probable causes to have minor antibody response found in males, older ages, individuals with BMI ≥ 25, those without past history of COVID-19 and with hematologic cancers. No significant side effects after vaccination were seen.

查看译文

关键词

COVID-19 vaccine,SARS-CoV-2,Sinopharm (BBIBP-CorV),anti-N IgG,anti-sRBD antibody response,cancer,seroconversion

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要